Loading...
Respiratory syncytial virus (RSV) causes devastating infections among infants and older people. Until now, the illness was not vaccine-preventable in either age group. In fall 2023, though, clinicians should be able to choose between two single-dose RSV vaccines for older adults.
Glaxo's Arexvy vaccine was U.S. FDA approved in May 2023, based largely on an interim analysis of an international phase 3 trial in about 25,000 older adults (age, ≥60). The vaccine showed ≈70% protective efficacy against all infections, ≈80% efficacy against lower respiratory tract infections (LTRIs), and almost 95% efficacy against severe LRTIs. Few very frail individuals or people older than 80 were enrolled, so efficacy in these high-risk subgroups could not be …